Diana Do, MD, provides an overview of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Back
The Role of Anti-VEGF/Angiopoiten-2 Inhibition for the Treatment of AMD and DME
Experts discuss the challenges of treatment burden in retinal disease management, emphasizing the importance of personalized treatment strategies to optimize patient outcomes. They also explore the role of shared decision-making and strategies for improving health literacy and numeracy in patient communication.
The Role of Anti-VEGF/Angiopoiten-2 Inhibition for the Treatment of AMD and DME
Episodes
All
All
Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).
Matthew Cunningham, MD, FASRS, provides the highlights of the YOSEMITE and RHINE trials for patients with diabetic macular edema (DME).
Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy
2
Nerandomilast Reduces Mortality Risk in Pulmonary Fibrosis Analysis
3
6 Cardiology Headlines You Missed in July 2026
4
What EASI 75, vIGA-AD Scores Reveal About Tapinarof's Eczema Efficacy
5